{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-125390","form_type":"8-K","ticker":"AURA","cik":"0001501796","company_name":"Aura Biosciences, Inc.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.611464+00:00","generated_at":"2026-05-30T01:48:49.607170+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Aura Biosciences Q3 net loss $21M; cash $174.4M; Phase 3 CoMpass authorized in Europe","bullets":["Net loss $21.0M (Q3 2024) vs $18.5M YoY; cash $174.4M funds operations into 2H 2026.","Phase 2 end-of-study: 80% tumor control, 90% visual acuity preservation in early-stage choroidal melanoma.","Phase 3 CoMpass trial authorized to enroll in Europe; >100 patients pre-screened globally.","Phase 1 NMIBC: 4/5 low-grade clinical complete responses; immune activation field effect observed.","Appointed Sabine Brookman-May as SVP, Therapeutic Area Head Urologic Oncology."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-125390","json":"https://secwatch.observer/filing/0000950170-24-125390.json","markdown":"https://secwatch.observer/filing/0000950170-24-125390.md","text":"https://secwatch.observer/filing/0000950170-24-125390.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501796/000095017024125390/0000950170-24-125390-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501796/000095017024125390/aura-20241112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T01:48:49.607170+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}